Role of Fibrinogen-Like Protein 2 Prothrombinase/Fibroleukin in Experimental and Human Allograft Rejection
- 1 June 2005
- journal article
- Published by The American Association of Immunologists in The Journal of Immunology
- Vol. 174 (11), 7403-7411
- https://doi.org/10.4049/jimmunol.174.11.7403
Abstract
Immune coagulation is a major contributor to the pathogenesis of xenograft rejection, viral-induced hepatocellular injury and cytokine-induced fetal loss syndrome. In this study, we investigated the contribution of the novel gene product, fibrinogen-like protein 2 (fgl2) prothrombinase, in mediating immune injury in experimental and human acute allograft rejection. Using a mouse heterotopic cardiac transplant model, mouse fgl2(mfgl2)/fibroleukin mRNA transcripts and protein were highly expressed in macrophages, CD4- and CD8-positive T lymphocytes, and endothelial cells in rejecting cardiac allografts in association with deposits of fibrin. Although mfgl2-deficient mice rejected allografts at similar rates to littermate controls, survival of grafts from mfgl2-deficient mice were prolonged and deposition of intravascular fibrin was diminished. Treatment of wild-type mice with a neutralizing anti-fgl2 Ab ameliorated histological evidence for allorejection and intravascular fibrin deposition, and resulted in an increase in graft survival. To address further the relevance of fgl2 in acute allograft rejection, we examined kidney biopsies from patients who had undergone renal transplantation. Human fgl2 mRNA transcripts and protein were markedly expressed mainly in renal tubule cells, infiltrating lymphoid cells including macrophages, CD8+ T cells, mature B cells (plasma cells), and endothelial cells. Dual staining showed fibrin deposition was localized mainly to blood vessels, in the glomerulus and interstitium and the lumen of tubules, and occurred in association with human fgl2 expression. These data collectively suggest that fgl2 accounts for the fibrin deposition seen in both experimental and human allograft rejection and provide a rationale for targeting fgl2 as adjunctive therapy to treat allograft rejection.Keywords
This publication has 23 references indexed in Scilit:
- Not just angiogenesis?wider roles for the angiopoietinsThe Journal of Pathology, 2003
- Induction of Prothrombinase fgl2 by the Nucleocapsid Protein of Virulent Mouse Hepatitis Virus Is Dependent on Host Hepatic Nuclear Factor-4αJournal of Biological Chemistry, 2003
- PROTEASE-ACTIVATED RECEPTOR 1 AND PLASMINOGEN ACTIVATOR INHIBITOR 1 EXPRESSION IN CHRONIC ALLOGRAFT NEPHROPATHYTransplantation, 2001
- Genomic Characterization, Localization, and Functional Expression of FGL2, the Human Gene Encoding Fibroleukin: A Novel Human ProcoagulantGenomics, 2001
- Molecular and Functional Analysis of the Human Prothrombinase Gene (HFGL2) and Its Role in Viral HepatitisThe American Journal of Pathology, 2000
- The Nucleocapsid Protein of Murine Hepatitis Virus Type 3 Induces Transcription of the Novel fgl2 Prothrombinase GenePublished by Elsevier ,1999
- The Banff 97 working classification of renal allograft pathologyKidney International, 1999
- Monoclonal antiprothrombinase (3D4.3) prevents mortality from murine hepatitis virus (MHV-3) infection.The Journal of Experimental Medicine, 1992
- A TECHNIQUE OF CERVICAL HETEROTOPIC HEART TRANSPLANTATION IN MICETransplantation, 1991
- Murine lymphoid procoagulant activity induced by bacterial lipopolysaccharide and immune complexes is a monocyte prothrombinaseThe Journal of Experimental Medicine, 1982